Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.
All entries for: Inozyme Pharma
April 29, 2025
Inozyme Pharma
Negative Outlook
Boston, MA
51-200 employees
Disease Area: Cardiology, Metabolic Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic